The EVI 2015 Annual Report provides a detailed insight into all of EVI's activities, projects, important meetings etc. We hope you will find it not only enlightening, but interesting reading.
New article published on 30 August 2016 in Malaria Journal emanating from EVI project AMA1
The Royal College of Surgeons in Ireland (RCSI) Strategic Academic Recruitment (StAR) currently has a Research Lecturer Recruitment Campaign with deadline 13 Setpember.
The MAlaria Research CApacity Development consortium (MARCAD) is currently calling for applications for 5 PhD and 10 post Postdoctoral Fellowships. Deadline: 31 August 2016
A publication emerging from the InnoMalVac project entitled "Production of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line system" has recently been published in Nature/scientific reports.
SAP SE which stands for “System analyses and Programme networking; Systems, Applications & Products in Data Processing” has published a news blog on diseases of poverty together with EVI, which is being made available to German/UK/US news outlets by SAP. EVI has adopted SAP Business ByDesign for its financial management, and is very grateful for the generous support of SAP.
German speakers please click here
On a sad note, EVI brings news of the death of Dr Egeruan Babatunde Imoukuede. Tunde, as he was known to his friends, joined EVI in 2005 as Clinical and Regulatory Affairs Director. He left in 2013 to work for the Jenner Institute at University of Oxford. Babatunde was a brilliant advocate for the battle against diseases of poverty. During all the years he was fighting for his life, he was an example of resilience and professionalism. He will be remembered at EVI for his persistent committment to research and development of malaria vaccines.
ExpreS2ion Biotech announces the second successful evaluation of safety by the independent safety monitoring board for the phase Ia clinical trial of the placental malaria vaccine candidate, PAMVAC. Due to the trial’s staggered approach, the second evaluation allows initiation of the phase Ib clinical trial to be conducted in Benin, Africa. The clinical trial is funded by the EU under the FP7 program and coordinated by associate professor Morten A Nielsen at University of Copenhagen in collaboration with University of Tübingen, Université d'Abomey-Calavi, European Vaccine Initiative, Institut de Recherche pour le Développement, and ExpreS2ion Biotech.
This year’s Sofja Kovalevskaja awardees have been anounced. Dr. Faith Osier (Kenya Medical Research Institute (KEMRI), Kilifi) is among them. Her project in the Parasitology Department at the UniversitätsKlinikum Heidelberg will commence in November 2016. For further information on the laureates see Humboldt homepage
This year’s BELLEROPHON annual meeting took place 07-08 July in Heidelberg, Germany. Staying at the ‘Internationales Wissenschaftsforum’ in the old town of Heidelberg allowed the participants to discuss the scientific progress in a charming and pleasant atmosphere.